Fig. 7From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphomaTornado diagram displaying the ICER sensitivity to the ten most influential model inputs. ICER, incremental cost-effectiveness ratio; IV, intravenous; OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone; VR-CAP, bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisoneBack to article page